Share Price and Basic Stock Data
Last Updated: January 29, 2026, 10:48 am
| PEG Ratio | -2.80 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lyka Labs Ltd operates in the pharmaceuticals industry, with a current market capitalization of ₹266 Cr and a share price of ₹75.00. The company has shown fluctuating revenue performance over recent quarters. Sales reported for September 2023 stood at ₹27.99 Cr, increasing to ₹32.56 Cr by December 2023. However, the revenue trajectory faced setbacks in earlier quarters, with sales declining to ₹17.82 Cr in December 2022 before recovering. The company’s trailing twelve months (TTM) revenue reached ₹137 Cr, reflecting a gradual recovery from a low of ₹93 Cr in March 2023. This upward trend indicates a potential stabilization in revenue generation, although the operating profit margin (OPM) remains negative at -6.93%. The company’s ability to maintain consistent revenue growth will be critical in improving its overall financial health.
Profitability and Efficiency Metrics
Profitability metrics for Lyka Labs indicate a challenging environment. The company reported a net profit of ₹2 Cr, which translates to an earnings per share (EPS) of ₹2.22 for March 2025. However, the net profit figures have seen volatility, with substantial losses recorded in previous periods, including a net loss of ₹10.42 Cr in December 2022. The interest coverage ratio (ICR) stood at 8.87x, suggesting that the company is capable of meeting its interest obligations comfortably. The return on equity (ROE) was recorded at 9.31%, while the return on capital employed (ROCE) was slightly higher at 9.91%. These figures are relatively modest compared to sector norms, indicating that while the company has begun to recover, profitability remains a significant concern that needs addressing to enhance stakeholder confidence.
Balance Sheet Strength and Financial Ratios
Lyka Labs’ balance sheet reflects a mixture of strengths and weaknesses. The company has total borrowings of ₹32 Cr against reserves of ₹65 Cr, indicating a manageable debt level. The current ratio is reported at 1.45, suggesting adequate short-term liquidity. However, the price-to-book value ratio (P/BV) stands at 3.48x, which is high compared to typical pharmaceutical industry benchmarks, indicating potential overvaluation concerns. The cash conversion cycle (CCC) is reported at 97 days, which is relatively high and suggests inefficiencies in working capital management. Additionally, the asset turnover ratio of 0.83% indicates that the company is generating ₹0.83 in revenue for every ₹1 of assets, which is below the industry average and highlights potential underutilization of assets.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lyka Labs reveals a strong promoter presence, holding 58.16% of the total shares, which indicates a solid commitment from the management. Foreign institutional investors (FIIs) hold a mere 0.17%, while domestic institutional investors (DIIs) account for 0.66%. The public holds 40.99% of the shares, with the total number of shareholders reported at 27,743. This distribution suggests that while promoter confidence is high, the lack of institutional investment may point to concerns over the company’s financial stability and growth potential. The gradual increase in promoter shareholding from 47.58% in December 2022 to the current level could be interpreted as a positive signal, reflecting management’s belief in the company’s future prospects amidst fluctuating performance metrics.
Outlook, Risks, and Final Insight
Looking ahead, Lyka Labs faces both opportunities and challenges. On one hand, the recent upward trend in sales and a positive net profit for March 2025 suggest potential recovery. On the other hand, risks include the high operating loss margins, volatility in profitability, and the elevated P/BV ratio, which could deter new investments. The company must focus on improving operational efficiencies to enhance its profitability and manage its working capital more effectively. If Lyka Labs successfully addresses these weaknesses, it could position itself for a stronger market presence. Conversely, failure to improve profitability and efficiency may lead to continued financial instability, limiting its growth potential in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 197/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,378 Cr. | 310 | 479/192 | 70.0 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.7 Cr. | 45.4 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 69.6 Cr. | 47.5 | 47.6/17.0 | 166 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,348.44 Cr | 1,074.12 | 47.21 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.53 | 17.82 | 22.24 | 22.88 | 27.99 | 32.56 | 27.77 | 30.11 | 41.16 | 33.80 | 33.43 | 33.03 | 36.66 |
| Expenses | 20.50 | 15.61 | 18.94 | 20.24 | 23.82 | 25.69 | 25.75 | 26.40 | 36.21 | 28.61 | 29.35 | 29.35 | 39.20 |
| Operating Profit | 5.03 | 2.21 | 3.30 | 2.64 | 4.17 | 6.87 | 2.02 | 3.71 | 4.95 | 5.19 | 4.08 | 3.68 | -2.54 |
| OPM % | 19.70% | 12.40% | 14.84% | 11.54% | 14.90% | 21.10% | 7.27% | 12.32% | 12.03% | 15.36% | 12.20% | 11.14% | -6.93% |
| Other Income | 0.98 | -5.95 | 0.02 | 0.38 | -0.18 | 0.54 | 0.32 | 0.56 | 0.03 | 0.83 | 0.82 | 0.63 | 1.09 |
| Interest | 3.03 | 3.08 | 2.85 | 1.35 | 1.19 | 1.28 | 1.07 | 0.65 | 0.54 | 0.61 | 0.47 | 0.85 | 0.79 |
| Depreciation | 3.62 | 3.47 | 3.47 | 3.47 | 3.59 | 2.84 | 2.90 | 1.76 | 1.76 | 1.83 | 1.42 | 2.11 | 2.15 |
| Profit before tax | -0.64 | -10.29 | -3.00 | -1.80 | -0.79 | 3.29 | -1.63 | 1.86 | 2.68 | 3.58 | 3.01 | 1.35 | -4.39 |
| Tax % | -46.88% | 2.24% | 0.00% | 7.22% | -22.78% | 38.60% | 28.22% | 30.65% | 28.36% | 24.30% | 32.89% | 26.67% | -26.65% |
| Net Profit | -0.38 | -10.42 | -3.01 | -1.85 | -0.49 | 1.78 | -2.09 | 1.29 | 1.91 | 2.70 | 2.03 | 0.99 | -3.22 |
| EPS in Rs | -0.13 | -3.63 | -0.98 | -0.56 | -0.15 | 0.54 | -0.63 | 0.40 | 0.59 | 0.76 | 0.50 | 0.26 | -0.94 |
Last Updated: January 11, 2026, 2:17 pm
Below is a detailed analysis of the quarterly data for Lyka Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 36.66 Cr.. The value appears strong and on an upward trend. It has increased from 33.03 Cr. (Jun 2025) to 36.66 Cr., marking an increase of 3.63 Cr..
- For Expenses, as of Sep 2025, the value is 39.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.35 Cr. (Jun 2025) to 39.20 Cr., marking an increase of 9.85 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.54 Cr.. The value appears to be declining and may need further review. It has decreased from 3.68 Cr. (Jun 2025) to -2.54 Cr., marking a decrease of 6.22 Cr..
- For OPM %, as of Sep 2025, the value is -6.93%. The value appears to be declining and may need further review. It has decreased from 11.14% (Jun 2025) to -6.93%, marking a decrease of 18.07%.
- For Other Income, as of Sep 2025, the value is 1.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.63 Cr. (Jun 2025) to 1.09 Cr., marking an increase of 0.46 Cr..
- For Interest, as of Sep 2025, the value is 0.79 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.85 Cr. (Jun 2025) to 0.79 Cr., marking a decrease of 0.06 Cr..
- For Depreciation, as of Sep 2025, the value is 2.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.11 Cr. (Jun 2025) to 2.15 Cr., marking an increase of 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is -4.39 Cr.. The value appears to be declining and may need further review. It has decreased from 1.35 Cr. (Jun 2025) to -4.39 Cr., marking a decrease of 5.74 Cr..
- For Tax %, as of Sep 2025, the value is -26.65%. The value appears to be improving (decreasing) as expected. It has decreased from 26.67% (Jun 2025) to -26.65%, marking a decrease of 53.32%.
- For Net Profit, as of Sep 2025, the value is -3.22 Cr.. The value appears to be declining and may need further review. It has decreased from 0.99 Cr. (Jun 2025) to -3.22 Cr., marking a decrease of 4.21 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.94. The value appears to be declining and may need further review. It has decreased from 0.26 (Jun 2025) to -0.94, marking a decrease of 1.20.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:02 am
| Metric | Jun 2014n n 15m | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 119 | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 137 |
| Expenses | 111 | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 127 |
| Operating Profit | 8 | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | 10 |
| OPM % | 7% | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% | 13% | 8% |
| Other Income | 25 | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | 3 |
| Interest | 27 | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 3 |
| Depreciation | 9 | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 8 |
| Profit before tax | -3 | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | 4 |
| Tax % | 45% | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | 29% | |
| Net Profit | -5 | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | 2 |
| EPS in Rs | -3.05 | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.24 | 0.58 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -171.43% | 68.42% | -950.00% | 84.13% | 480.00% | -134.21% | 76.92% | 366.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 239.85% | -1018.42% | 1034.13% | 395.87% | -614.21% | 211.13% | 289.74% |
Lyka Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 18% |
| 3 Years: | -11% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 18% |
| 3 Years: | -43% |
| TTM: | 681% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 39% |
| 3 Years: | -13% |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| Last Year: | 9% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:35 am
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 | 36 |
| Reserves | 30 | 20 | 22 | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 68 | 65 |
| Borrowings | 164 | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 | 32 |
| Other Liabilities | 113 | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 33 | 35 |
| Total Liabilities | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 168 |
| Fixed Assets | 162 | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 85 | 87 |
| CWIP | 22 | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 145 | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 | 80 |
| Total Assets | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 168 |
Below is a detailed analysis of the balance sheet data for Lyka Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 36.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 36.00 Cr..
- For Reserves, as of Sep 2025, the value is 65.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to 65.00 Cr., marking a decrease of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 32.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2025) to 32.00 Cr., marking a decrease of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 35.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 168.00 Cr.. The value appears to be improving (decreasing). It has decreased from 176.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 8.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 87.00 Cr.. The value appears strong and on an upward trend. It has increased from 85.00 Cr. (Mar 2025) to 87.00 Cr., marking an increase of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 80.00 Cr.. The value appears to be declining and may need further review. It has decreased from 90.00 Cr. (Mar 2025) to 80.00 Cr., marking a decrease of 10.00 Cr..
- For Total Assets, as of Sep 2025, the value is 168.00 Cr.. The value appears to be declining and may need further review. It has decreased from 176.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 8.00 Cr..
Notably, the Reserves (65.00 Cr.) exceed the Borrowings (32.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Jun 2014n n 15m | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 8.00 | -109.00 | 20.00 | -103.00 | -117.00 | -98.00 | -145.00 | -143.00 | -29.00 | -58.00 | -43.00 | -21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209 | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 | 114 |
| Inventory Days | 91 | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 | 82 |
| Days Payable | 363 | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 | 98 |
| Cash Conversion Cycle | -64 | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 | 97 |
| Working Capital Days | -309 | -220 | -242 | -357 | -735 | -265 | -242 | -118 | -121 | -0 | 23 | 51 |
| ROCE % | 2% | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.22 | -0.79 | -4.63 | 13.57 | -4.07 |
| Diluted EPS (Rs.) | 2.22 | -0.79 | -4.63 | 13.57 | -4.07 |
| Cash EPS (Rs.) | 4.12 | 3.08 | 0.32 | 19.45 | -0.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 29.01 | 20.60 | 14.81 | 4.70 | -8.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 29.01 | 20.60 | 14.81 | 4.70 | -8.75 |
| Revenue From Operations / Share (Rs.) | 38.81 | 33.60 | 30.33 | 67.65 | 30.06 |
| PBDIT / Share (Rs.) | 5.65 | 5.19 | 6.59 | 35.99 | 7.41 |
| PBIT / Share (Rs.) | 3.75 | 1.32 | 1.99 | 29.94 | 4.50 |
| PBT / Share (Rs.) | 3.12 | -0.28 | -4.29 | 20.65 | -4.93 |
| Net Profit / Share (Rs.) | 2.22 | -0.79 | -4.29 | 13.40 | -3.52 |
| NP After MI And SOA / Share (Rs.) | 2.24 | -0.75 | -4.30 | 13.59 | -4.03 |
| PBDIT Margin (%) | 14.56 | 15.44 | 21.74 | 53.19 | 24.63 |
| PBIT Margin (%) | 9.67 | 3.92 | 6.54 | 44.25 | 14.98 |
| PBT Margin (%) | 8.03 | -0.83 | -14.15 | 30.52 | -16.39 |
| Net Profit Margin (%) | 5.72 | -2.35 | -14.13 | 19.80 | -11.69 |
| NP After MI And SOA Margin (%) | 5.78 | -2.23 | -14.19 | 20.09 | -13.39 |
| Return on Networth / Equity (%) | 7.73 | -3.65 | -29.07 | 292.38 | 0.00 |
| Return on Capital Employeed (%) | 10.33 | 3.66 | 5.12 | 99.57 | 9.17 |
| Return On Assets (%) | 4.54 | -1.58 | -8.71 | 21.01 | -6.08 |
| Long Term Debt / Equity (X) | 0.17 | 0.61 | 1.38 | 4.63 | -5.84 |
| Total Debt / Equity (X) | 0.35 | 0.81 | 1.55 | 9.66 | -6.24 |
| Asset Turnover Ratio (%) | 0.83 | 0.72 | 0.55 | 0.82 | 0.30 |
| Current Ratio (X) | 1.45 | 1.35 | 1.36 | 0.52 | 0.59 |
| Quick Ratio (X) | 1.18 | 1.09 | 1.14 | 0.44 | 0.50 |
| Inventory Turnover Ratio (X) | 12.57 | 13.46 | 3.05 | 4.31 | 2.23 |
| Interest Coverage Ratio (X) | 8.87 | 3.51 | 1.71 | 5.13 | 0.81 |
| Interest Coverage Ratio (Post Tax) (X) | 4.49 | 0.54 | 0.51 | 3.23 | 0.65 |
| Enterprise Value (Cr.) | 396.90 | 401.32 | 381.55 | 501.74 | 229.87 |
| EV / Net Operating Revenue (X) | 2.87 | 3.61 | 4.10 | 2.59 | 2.67 |
| EV / EBITDA (X) | 19.68 | 23.37 | 18.85 | 4.86 | 10.82 |
| MarketCap / Net Operating Revenue (X) | 2.60 | 3.15 | 3.45 | 2.00 | 0.86 |
| Price / BV (X) | 3.48 | 5.14 | 7.07 | 29.17 | -2.89 |
| Price / Net Operating Revenue (X) | 2.60 | 3.15 | 3.45 | 2.00 | 0.86 |
| EarningsYield | 0.02 | -0.01 | -0.04 | 0.10 | -0.15 |
After reviewing the key financial ratios for Lyka Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 5. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 5. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.12. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 4.12, marking an increase of 1.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.01. It has increased from 20.60 (Mar 24) to 29.01, marking an increase of 8.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 29.01. It has increased from 20.60 (Mar 24) to 29.01, marking an increase of 8.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 38.81. It has increased from 33.60 (Mar 24) to 38.81, marking an increase of 5.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 5.19 (Mar 24) to 5.65, marking an increase of 0.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.75. This value is within the healthy range. It has increased from 1.32 (Mar 24) to 3.75, marking an increase of 2.43.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.12. This value is within the healthy range. It has increased from -0.28 (Mar 24) to 3.12, marking an increase of 3.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.22. This value is within the healthy range. It has increased from -0.79 (Mar 24) to 2.22, marking an increase of 3.01.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.24. This value is within the healthy range. It has increased from -0.75 (Mar 24) to 2.24, marking an increase of 2.99.
- For PBDIT Margin (%), as of Mar 25, the value is 14.56. This value is within the healthy range. It has decreased from 15.44 (Mar 24) to 14.56, marking a decrease of 0.88.
- For PBIT Margin (%), as of Mar 25, the value is 9.67. This value is below the healthy minimum of 10. It has increased from 3.92 (Mar 24) to 9.67, marking an increase of 5.75.
- For PBT Margin (%), as of Mar 25, the value is 8.03. This value is below the healthy minimum of 10. It has increased from -0.83 (Mar 24) to 8.03, marking an increase of 8.86.
- For Net Profit Margin (%), as of Mar 25, the value is 5.72. This value is within the healthy range. It has increased from -2.35 (Mar 24) to 5.72, marking an increase of 8.07.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.78. This value is below the healthy minimum of 8. It has increased from -2.23 (Mar 24) to 5.78, marking an increase of 8.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.73. This value is below the healthy minimum of 15. It has increased from -3.65 (Mar 24) to 7.73, marking an increase of 11.38.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.33. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 10.33, marking an increase of 6.67.
- For Return On Assets (%), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has increased from -1.58 (Mar 24) to 4.54, marking an increase of 6.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.17. This value is below the healthy minimum of 0.2. It has decreased from 0.61 (Mar 24) to 0.17, marking a decrease of 0.44.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.35. This value is within the healthy range. It has decreased from 0.81 (Mar 24) to 0.35, marking a decrease of 0.46.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.72 (Mar 24) to 0.83, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.35 (Mar 24) to 1.45, marking an increase of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.18, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 12.57. This value exceeds the healthy maximum of 8. It has decreased from 13.46 (Mar 24) to 12.57, marking a decrease of 0.89.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.87. This value is within the healthy range. It has increased from 3.51 (Mar 24) to 8.87, marking an increase of 5.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.49. This value is within the healthy range. It has increased from 0.54 (Mar 24) to 4.49, marking an increase of 3.95.
- For Enterprise Value (Cr.), as of Mar 25, the value is 396.90. It has decreased from 401.32 (Mar 24) to 396.90, marking a decrease of 4.42.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.61 (Mar 24) to 2.87, marking a decrease of 0.74.
- For EV / EBITDA (X), as of Mar 25, the value is 19.68. This value exceeds the healthy maximum of 15. It has decreased from 23.37 (Mar 24) to 19.68, marking a decrease of 3.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.60, marking a decrease of 0.55.
- For Price / BV (X), as of Mar 25, the value is 3.48. This value exceeds the healthy maximum of 3. It has decreased from 5.14 (Mar 24) to 3.48, marking a decrease of 1.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 3.15 (Mar 24) to 2.60, marking a decrease of 0.55.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.02, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lyka Labs Ltd:
- Net Profit Margin: 5.72%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.33% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.73% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.49
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 131 (Industry average Stock P/E: 47.21)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.35
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.72%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 4801/B & 4802/A, Ankleshwar Gujarat 393002 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Babulal Jain | Chairman |
| Mr. Kunal Gandhi | Managing Director & CEO |
| Mr. Yogesh B Shah | WholeTime Director & CFO |
| Mr. Shashil Mendosa | Non Executive Director |
| Mr. Prashant Godha | Non Executive Director |
| Mrs. Dhara Shah | Independent Director |
| Mr. Neeraj Golas | Independent Director |
| Ms. Archana S Yadav | Independent Director |
FAQ
What is the intrinsic value of Lyka Labs Ltd?
Lyka Labs Ltd's intrinsic value (as of 29 January 2026) is ₹149.88 which is 100.64% higher the current market price of ₹74.70, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹267 Cr. market cap, FY2025-2026 high/low of ₹157/71.3, reserves of ₹65 Cr, and liabilities of ₹168 Cr.
What is the Market Cap of Lyka Labs Ltd?
The Market Cap of Lyka Labs Ltd is 267 Cr..
What is the current Stock Price of Lyka Labs Ltd as on 29 January 2026?
The current stock price of Lyka Labs Ltd as on 29 January 2026 is ₹74.7.
What is the High / Low of Lyka Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lyka Labs Ltd stocks is ₹157/71.3.
What is the Stock P/E of Lyka Labs Ltd?
The Stock P/E of Lyka Labs Ltd is 131.
What is the Book Value of Lyka Labs Ltd?
The Book Value of Lyka Labs Ltd is 28.3.
What is the Dividend Yield of Lyka Labs Ltd?
The Dividend Yield of Lyka Labs Ltd is 0.00 %.
What is the ROCE of Lyka Labs Ltd?
The ROCE of Lyka Labs Ltd is 9.91 %.
What is the ROE of Lyka Labs Ltd?
The ROE of Lyka Labs Ltd is 9.31 %.
What is the Face Value of Lyka Labs Ltd?
The Face Value of Lyka Labs Ltd is 10.0.